Tropisetron improves deficits in auditory P50 suppression in schizophrenia
about
A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophreniaThe 5-HT3 receptor as a therapeutic targetThe human CHRNA7 and CHRFAM7A genes: A review of the genetics, regulation, and functionNicotinic acetylcholine receptor ligands, a patent review (2006-2011)Sensory disturbances, inhibitory deficits, and the P50 wave in schizophreniaA placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenianAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disordersEffects of the nicotinic α7 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in ratsTranslational utility of rodent hippocampal auditory gating in schizophrenia research: a review and evaluation.Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptorBeyond the dopamine receptor: novel therapeutic targets for treating schizophrenia.Ondansetron results in improved auditory gating in DBA/2 mice through a cholinergic mechanismSmoking, Genetics and Schizophrenia: Evidence for Self Medication.Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.Design, synthesis, and activity of a series of arylpyrid-3-ylmethanones as type I positive allosteric modulators of α7 nicotinic acetylcholine receptors.[11C]CHIBA-1001 as a novel PET ligand for alpha7 nicotinic receptors in the brain: a PET study in conscious monkeys.Nicotinic Receptors: Role in Addiction and Other Disorders of the Brain.Reduced CHRNA7 expression in C3H mice is associated with increases in hippocampal parvalbumin and glutamate decarboxylase-67 (GAD67) as well as altered levels of GABA(A) receptor subunits.α7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer's Disease.Discovery, synthesis, biological evaluation and structure-based optimization of novel piperidine derivatives as acetylcholine-binding protein ligands.5-HT3a Receptors Modulate Hippocampal Gamma Oscillations by Regulating Synchrony of Parvalbumin-Positive Interneurons.Occupancy of α7 Nicotinic Acetylcholine Receptors in the Brain by Tropisetron: A Positron Emission Tomography Study Using [(11)C]CHIBA-1001 in Healthy Human SubjectsRecent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.Medications Development for the Treatment of Nicotine Dependence in Individuals with Schizophrenia.Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational BiomarkerNicotinic receptors containing the alpha7 subunit: a model for rational drug design.Role of the cholinergic system in the pathology and treatment of schizophrenia.The treatment of cognitive impairment in schizophrenia.A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia.Novel approaches to drug design for the treatment of schizophrenia.The development of novel polypharmacological agents targeting the multiple binding sites of nicotinic acetylcholine receptors.Continuous administration of a selective alpha7 nicotinic partial agonist, DMXBA, improves sensory inhibition without causing tachyphylaxis or receptor upregulation in DBA/2 mice.Sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague-Dawley rats.The alpha-7 nicotinic receptor partial agonist/5-HT3 antagonist RG3487 enhances cortical and hippocampal dopamine and acetylcholine release.Tropisetron and its targets in Alzheimer's disease.
P2860
Q21203917-FD9495DC-3247-4C9F-B988-AD7C74D9B6DCQ24681066-8B0C829A-3629-4D70-AE84-24AD84C112FDQ26821785-EF7DB2C7-B6F7-4E76-B84F-F7A19AFDCF68Q26824360-24E8BC58-4D01-40A7-8591-1BE29B6F07CBQ27026737-63AB74EA-7ADF-42E6-B9B1-B21566682302Q28287576-14E38AE1-76F2-487F-BE9C-1349B0F3F47AQ30362464-BA9229EB-61E4-41B8-B451-93D1D534FD05Q30372351-D518F117-135D-468B-A09F-D308C77348EAQ30391389-5E27E07B-CF2C-4EEC-8622-725A0B6BEEB6Q30407039-F3291A83-0848-4924-A010-828008F50E4BQ30453198-4C4F5EA3-C8EE-42DE-B596-71787C634ADFQ30473410-E6FFEB0C-A85B-42B1-94C4-4C4B92688623Q30478352-A1DD08B0-B994-4420-ADFA-03D855ACAFECQ30491841-52002658-5043-4B78-98D0-31A0DBB81311Q30493072-1BD6FED5-016F-47F1-9DF8-3C01C18E0DBAQ30570721-6A19CEB1-5B1B-4371-94C3-68657327E06BQ33370286-F5BA549C-3ABC-48E9-B614-519D2F62FB64Q33635666-BB053C8D-678D-4C80-8EA0-E3629D67C112Q34004330-E69D931E-DBDE-46F2-BCA5-01EE1A4AE84FQ34501147-E02CEB10-6119-4C32-90C7-160A6D0C0EEDQ36213170-60753A43-B85C-480D-95E5-AC589C8F1CDEQ36462376-E849174E-6BC5-4CD5-BAF1-3D6C8632FD44Q36600684-940F0516-B002-4022-915B-2C0F6B027793Q36886717-E85B6582-CF56-4BEE-87F3-2AA449F02E41Q36917265-B711259F-98F1-43DB-BE6C-221DD00639C2Q37079797-264E6893-2FBF-4840-A52F-38C0107A43AFQ37258840-04F5DFA2-0AE1-43BE-AAF8-25CA36571B4CQ37347201-3E98A88E-0DA1-41B0-9870-E72F433BC4CEQ37356496-87B9E361-8FCB-4F3E-9A07-C36BC95C4E54Q37813206-46EDAB90-6D3D-4E45-9273-8C9748957C68Q37962995-1DF2F68C-91DB-4A0F-AC15-E0884DD2649DQ38122451-94D0B064-6E78-49FB-9BAC-7386C31CCD6CQ38934855-E362EE32-AC94-44DC-8124-98C88CF0E4B7Q41974120-415D26EA-B97F-4D01-B14B-5F173D418800Q42754120-04B01033-2C37-4264-9EC4-DDBEE61E1A2EQ46082663-C3F1ABDA-96FF-4E1B-8DFA-299121672EE9Q50612380-E8A21DF2-3920-4874-AE74-E606729C3B89
P2860
Tropisetron improves deficits in auditory P50 suppression in schizophrenia
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Tropisetron improves deficits in auditory P50 suppression in schizophrenia
@ast
Tropisetron improves deficits in auditory P50 suppression in schizophrenia
@en
Tropisetron improves deficits in auditory P50 suppression in schizophrenia
@nl
type
label
Tropisetron improves deficits in auditory P50 suppression in schizophrenia
@ast
Tropisetron improves deficits in auditory P50 suppression in schizophrenia
@en
Tropisetron improves deficits in auditory P50 suppression in schizophrenia
@nl
prefLabel
Tropisetron improves deficits in auditory P50 suppression in schizophrenia
@ast
Tropisetron improves deficits in auditory P50 suppression in schizophrenia
@en
Tropisetron improves deficits in auditory P50 suppression in schizophrenia
@nl
P2093
P1476
Tropisetron improves deficits in auditory P50 suppression in schizophrenia
@en
P2093
Eiji Shimizu
Hiroyuki Watanabe
Kaori Koike
Karen E Stevens
Masaomi Iyo
Michiko Nakazato
Naoe Okamura
Naoya Komatsu
Nobuyuki Takai
Robert Freedman
P356
10.1016/J.SCHRES.2004.12.016
P407
P50
P577
2005-07-01T00:00:00Z